High-Risk Patients With Diffuse Large B-Cell Lymphoma Are Not Enrolled on Clinical Trials

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_42
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

BCL-2 Protein Frequency in Patients With High-Risk Diffuse Large B-Cell Lymphoma

Sao Paulo Medical Journal
Medicine
2010English

Plasma Immunoprofiling of Patients With High-Risk Diffuse Large B-Cell Lymphoma: A Nordic Lymphoma Group Study

Blood Cancer Journal
OncologyHematology
2016English

Clinical Significance of T-Cell Exhaustion in Patients With Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Diffuse Large B-Cell Lymphoma

2020English

Prognostic Value of Baseline FDG Pet Parameters in High Risk Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients With Diffuse Large B-Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Blood Lymphocyte-To-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated With R-Chop

PLoS ONE
Multidisciplinary
2012English

Impact of Comorbidities on Outcomes of Elderly Patients With Diffuse Large B-Cell Lymphoma

American Journal of Hematology
Hematology
2017English

Population Pharmacokinetics of Rituximab in Patients With Diffuse Large B-Cell Lymphoma and Association With Clinical Outcome

British Journal of Clinical Pharmacology
Pharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy